The study for adjunctive lithium for extended effect on antidepressant action of ketamine and its neural correlates.

Not Applicable

• Conditions: Treatment-resistant monopolar/bipolar depression

• Registration Number: JPRN-UMIN000017529
• Lead Sponsor: Kurume University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-05-12
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with any clinically significant psychiatric disorder other than ICD-10 criteria for F32, F33, F31. 2.Patients with Lifetime history of mood-incongruent psychotic features based on DSM-IV-TR. 3.Patients judged clinically to be at serious and imminent suicidal or homicidal risk. 4.Imminent risk of other harm. 5.Patients with any organic brain disease. 6.Patients with unstable medical illness. 7.Patients treated with lithium within two weeks of consent. 8.Patients who are intolerant to Ketamine or Lithium because of reasons below; thyroid dysfunction, parathyroid dysfunction, renal dysfunction, atrio-ventricular block, epilepsy, uncontrolled hypertension, adverse events in using ketamine or lithium ever before. 9.Women who are pregnant or who wish to become pregnant during the research.

Study & Design

• Study Type: Interventional
• Study Design: Not specified